RT Journal Article
SR Electronic
T1 Ultrasound and biochemical predictors of pregnancy outcome at diagnosis of early-onset fetal growth restriction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.27.23285087
DO 10.1101/2023.01.27.23285087
A1 Spencer, Rebecca
A1 Maksym, Kasia
A1 Hecher, Kurt
A1 Maršál, Karel
A1 Figueras, Francesc
A1 Ambler, Gareth
A1 Whitwell, Harry
A1 Nené, Nuno Rocha
A1 Sebire, Neil J.
A1 Hansson, Stefan R.
A1 Diemert, Anke
A1 Brodszki, Jana
A1 Gratacós, Eduard
A1 Ginsberg, Yuval
A1 Weissbach, Tal
A1 Peebles, Donald M
A1 Zachary, Ian
A1 Marlow, Neil
A1 Huertas-Ceballos, Angela
A1 David, Anna L.
YR 2023
UL http://medrxiv.org/content/early/2023/01/28/2023.01.27.23285087.abstract
AB Background Severe early-onset fetal growth restriction (FGR) causes significant fetal and neonatal mortality and morbidity. Predicting the outcome of affected pregnancies at the time of diagnosis is difficult, preventing accurate patient counselling. We investigated the use of maternal serum protein and ultrasound measures at diagnosis to predict fetal or neonatal death and three secondary outcomes: fetal death or delivery ≤28+0 weeks; development of abnormal umbilical artery Doppler velocimetry; slow fetal growth.Methods Women with singleton pregnancies (n=142, estimated fetal weights [EFWs] <3rd centile, <600g 20+0-26+6 weeks of gestation, no known chromosomal, genetic or major structural abnormalities), were recruited from four European centres. Maternal serum from the discovery set (n=63) was analysed for seven proteins linked to angiogenesis, 90 additional proteins associated with cardiovascular disease and five proteins identified through pooled liquid chromatography tandem mass spectrometry. Patient and clinician stakeholder priorities were used to select models tested in the validation set (n=60), with final models calculated from combined data.Results The most discriminative model for fetal or neonatal death included EFW z-score (Hadlock 3 formula/Marsal chart), gestational age and umbilical artery Doppler category (AUC 0.91, 95%CI 0.86-0.97) but was less well calibrated than the model containing only EFW z-score (Hadlock3/Marsal). The most discriminative model for fetal death or delivery ≤28+0 weeks included maternal serum placental growth factor (PlGF) concentration and umbilical artery Doppler category (AUC 0.89, 95%CI 0.83-0.94).Conclusion Ultrasound measurements and maternal serum PlGF concentration at diagnosis of severe early-onset FGR predict pregnancy outcomes of importance to patients and clinicians.Trial registration ClinicalTrials.gov NCT02097667Funding European Union, Rosetrees Trust, Mitchell Charitable Trust.Competing Interest StatementNM declares consultancy fees from InfanDx over the past 12 monthsClinical Protocols https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-017-1226-7 Funding StatementThe research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305823, the Rosetrees Trust and the Mitchell Charitable Trust in memory of Shoshana Mitchell Glynn. This research has been supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre (RS, NM, ALD). NRN would like to thank the support from Cancer Research UK (C12077/A26223).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Research Ethics Service Committee London - Stanmore gave ethical approval for this work in the UK (REC reference: 13/LO/1254) Hospital Clinic of Barcelona Clinical Research Ethics Committee gave ethical approval for this work in Spain (Reg: HCB/2014/0091) The Regional Ethical Review Board in Lund gave ethical approval for this work in Sweden (DNr 2014/147) The Ethics Committee of Hamburg Board of Physicians gave ethical approval for this work in Germany (PV4809)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full data set will not be made publicly available because the degree of detailed phenotyping could allow individual patient identification. Limited data sharing may be possible, with the agreement of the consortium, on request to RS or ALD.